Lenalidomide triggers ferroptosis in multiple myeloma by blocking the c-Maf/USP7 signaling pathway to induce the ubiquitination and degradation of FTH1.
Multiple myeloma (MM) is the second most common hematological malignancy. Ferroptosis, a distinct form of programmed cell death, has attracted the interest of researchers because of its unique role and biological significance across various diseases. As a first-line clinical treatment drug for MM, lenalidomide (LEN) ha...